-
eChanges September 2023
Inside this issue AMS News President's Report Updated AMS Information Sheet: Tibolone as menopausal hormone therapy 26th Annual Australasian Menopause Society Congress Synopsis New AMS Board Director: Dr Amie Hanlon AMS Congress Award and Prize Winnersn AMS Scholarship – Ms Celine Camon Menopause... eChanges September 2023 -
Menopause Essentials Update 2023
Saturday 4 November - 12.00-4.30pm Join us for lunch followed by an update on the essentials of menopause management. This workshop is aimed at GPs, gynaecologists, endocrinologists and other health professionals who are seeking a comprehensive review of the current issues that face them in the... Read more... -
FRAXplus®: Refining risk prediction
Accurate assessment of fracture risk is essential for optimal diagnosis and management of osteoporosis.The FRAX® fracture risk assessment tool has substantially improved the identification of people at high risk of fracture since its launch in 2008. To date, 86 FRAX models have been made available... FRAXplus®: Refining risk prediction -
Primary Ovarian Insufficiency
Loss of ovarian follicular activity (spontaneous or induced) before the age of 40 years constitutes primary ovarian insufficiency. It is characterized by hypergonadotropic hypogonadism (low estradiol and elevated gonadotropin levels) and results in loss of fertility and premature deficiency of... Primary Ovarian Insufficiency -
eChanges August 2023
Inside this issue AMS News President's Report Baseline (knowledge) and Basis (evidence) for Menopause Management New courses on AMS eLearning – Free for AMS members! Menopausal hormone therapy (MHT) patch shortages 26th AMS Congress, Queenstown, New Zealand, 1-3 September 2023 IMS World Congress on... eChanges August 2023 -
Menopause in the Workplace after COVID Webinar
Date: 7 September 2023 Time: 4.00 p.m. CET (Paris time) | 12.00 am AEST 8 September 2023 Speakers The webinar will be recorded and you will be notified of the recording if you register to attend. Menopause in the Workplace after COVID Webinar -
Hormone Therapy use in the Aging Transgender Woman
Sarah R Pickle, MD Associate Professor, Family and Community Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio Dr Sarah Pickle discusses the risks and benefits of hormone therapy use in the aging transgender woman. There is no age cut-off for gender-affirming hormone use, and almost... Hormone Therapy use in the Aging Transgender Woman -
MENO-D
By Dr Lina Safro The perimenopausal period encompasses a wide range of significant emotional symptoms. Listed in the AMS Score Sheet are the characteristic mood and cognitive changes including “brain fog”, irritability, “unloved feelings”, “anxiety” and “depression” (1). Studies indicate that... MENO-D -
eChanges July 2023
Inside this issue AMS News President's Report MENO-D Updated AMS Information Sheet: Osteoporosis Changes to AMS Guide to MHT/HRT Doses Call for Nominations - AMS Board Elections 2023-25 26th AMS Congress, Queenstown, New Zealand, 1-3 September 2023 AMS Scientific Publication Prize IMS World... eChanges July 2023 -
Genetic causes of POI - 11 July 2023
Moderator: Dr Wendy Wolfman Speakers: Prof Joop Laven: Advances in POI genetics Prof Randi Hagerman: Fragile X and POI Genetic causes of POI - 11 July 2023 -
Our Menopause World July 2023
Webinar recording Pay Attention on Your Way In! The vulva is an important organ too The recording of the June webinar, held by Professor Rossella Nappi, Doctor Jan Shifren and Doctor Tami Rowen is now available online. Watch Free access to selected papers recently published in Climacteric The June issue of... Our Menopause World July 2023 -
eChanges June 2023
Inside this issue AMS News President's Report Selecting the progestogen for menopausal hormone therapy Updated AMS Information Sheet: AMS Guide to MHT/HRT Doses King’s Birthday Honours Menopausal Hormone Therapy (MHT) Patch discontinuation and shortages 26th AMS Congress, Queenstown, New Zealand, 1-3... eChanges June 2023 -
Our Menopause World June 2023
President's Report General Update Dear Friends and Colleagues It gives me great pleasure to provide my latest president’s report for OMW in which I would particularly like to highlight the collaborative efforts of IMS to connect with our members and global partners. We are now approaching 1,000... Our Menopause World June 2023 -
Pay Attention on Your Way In! The vulva is an important organ too - 13 June 2023
Moderator: Prof Rossella Nappi Speakers: Dr Jan Shifren: Management of genitourinary syndrome of menopause Dr Tami Rowen: Dyspareunia and vulvodynia 13 June at 15:00 CEST | 23:00 PM (AEST) Duration: 1 hour Pay Attention on Your Way In! The vulva is an important organ too - 13 June 2023 -
The 2023 Nonhormone Therapy Position Statement of the North American Menopause Society
The North American Menopause Society has reviewed and evaluated the literature since publication of their 2015 Position Statement on Nonhormonal Management of Menopause-Associated Vasomotor Symptoms. Recommended options for evidence-based treatment of vasomotor symptoms include: Cognitive-behavioural... The 2023 Nonhormone Therapy Position Statement of the North American Menopause Society -
Our Menopause World May 2023
Free access to selected papers recently published in Climacteric By way of a special arrangement with our publishers, Taylor & Francis, our journal Climacteric is able to offer Free Access to some recently published papers for a limited time. Two papers from Climacteric 2023, Volume 26 - April... Our Menopause World May 2023 -
Evaluation and Treatment of Vulvovaginal Itching in Postmenopausal Women
Vulvovaginal itching is common in postmenopausal women. It may be because of the genitourinary syndrome of menopause, but there are also other causes as well, including infection, dermatoses, autoimmune disorders, dysplasia, vulvar cancer, or contact dermatitis. Comprehensive evaluation is... Evaluation and Treatment of Vulvovaginal Itching in Postmenopausal Women -
eChanges May 2023
Inside this issue AMS News President's Report Updated AMS Information Sheet: SERMS – their role in menopause management 25th AMS Congress, Cairns videos now available to AMS members only Menopausal Hormone Therapy (MHT) Patch discontinuation and shortages 26th AMS Congress, Queenstown, New... eChanges May 2023 -
Secondary causes of osteoporosis
Dr Sonia Davison Whilst most osteoporosis is due to a reduction in bone density from a combination of age and menopause, screening for secondary causes of osteoporosis is an important part of the assessment of women who are found to have osteoporosis. If a secondary cause of osteoporosis can be... Secondary causes of osteoporosis -
Lower back pain is worsened by inadequate vitamin D and obesity in postmenopausal women
13 March 2023 Summary Postmenopausal women are significantly more likely to suffer from vitamin D deficiency and obesity. It is common for postmenopausal women to have lower back pain (LBP), impaired muscle strength, and poor muscle function due to 25(OH)D deficiency. Obesity may also have a... Lower back pain is worsened by inadequate vitamin D and obesity in postmenopausal women
